These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 29719482)
1. First Results and Experience with PRRT in South Africa. Vorster M; Modiselle MR; Corbett CS; Lawal IO; Buscombe JR; Sathekge MM World J Nucl Med; 2018; 17(2):86-93. PubMed ID: 29719482 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of hitherto unknown brain meningioma detected on Parghane RV; Talole S; Basu S World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748 [TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant Ballal S; Yadav MP; Tripathi M; Sahoo RK; Bal C J Nucl Med; 2022 Jul; ():. PubMed ID: 35863893 [No Abstract] [Full Text] [Related]
5. Peptide Receptor Radionuclide Therapy Using Kalantarhormozi M; Hassanzadeh S; Rekabpour SJ; Ravanbod MR; Jafari E; Amini A; Dadgar H; Mahmoudpour M; Nabipour I; Jokar N; Assadi M World J Nucl Med; 2022 Sep; 21(3):215-221. PubMed ID: 36060085 [No Abstract] [Full Text] [Related]
6. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
7. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Parghane RV; Talole S; Prabhash K; Basu S Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500 [TBL] [Abstract][Full Text] [Related]
8. Thapa P; Parghane R; Basu S World J Nucl Med; 2017; 16(3):223-228. PubMed ID: 28670182 [TBL] [Abstract][Full Text] [Related]
9. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE. Basu S; Ranade R; Thapa P World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977 [TBL] [Abstract][Full Text] [Related]
11. The Safety and Efficacy of the Repeated PRRT with [ Zemczak A; Gut P; Pawlak D; Kołodziej M; Królicki L; Kos-Kudła B; Ruchała M; Kamiński G; Kunikowska J Int J Endocrinol; 2021; 2021():6615511. PubMed ID: 33552155 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Survival and Value of Rodrigues M; Winkler KK; Svirydenka H; Nilica B; Uprimny C; Virgolini I Life (Basel); 2021 Mar; 11(3):. PubMed ID: 33806393 [TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050 [TBL] [Abstract][Full Text] [Related]
15. Prediction of Lee H; Kipnis ST; Niman R; O'Brien SR; Eads JR; Katona BW; Pryma DA Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201627 [TBL] [Abstract][Full Text] [Related]
16. The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE. Soydal Ç; Peker A; Özkan E; Küçük ÖN; Kir MK Turk J Med Sci; 2016 Feb; 46(2):409-13. PubMed ID: 27511504 [TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic factors for PRRT in neuroendocrine tumors. Trautwein NF; Schwenck J; Jacoby J; Reischl G; Fiz F; Zender L; Dittmann H; Hinterleitner M; la Fougère C Front Med (Lausanne); 2023; 10():1169970. PubMed ID: 37359009 [TBL] [Abstract][Full Text] [Related]
18. Investigation of receptor radionuclide therapy with Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927 [TBL] [Abstract][Full Text] [Related]
19. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT. Zwirtz K; Hardt J; Acker G; Baur ADJ; Pavel M; Huang K; Brenner W; Prasad V Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745849 [No Abstract] [Full Text] [Related] [Next] [New Search]